RxDoctor Payments Data

Raynata Ramkhelawan, MD

Family Medicine · Rensselaer, NYNPI 1891358461

Payments from drug & device makers

$482in general payments, 2019–2025

Across 24 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$127
  • Lilly USA, LLC$72
  • Braeburn Inc.$50
  • Pfizer$37
  • Sanofi Pasteur Inc.$24
  • Indivior Inc.$23
  • plus $149 from 9 others

What the payments were for

  • Food & beverage$482100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$482 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$33,249
Medicare patients
269
Services billed
509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin74$78,787
JanuviaSitagliptin Phosphate37$48,132
TrulicityDulaglutide18$41,493
OzempicSemaglutide37$39,467
RybelsusSemaglutide19$25,031
EliquisApixaban19$24,027
ProliaDenosumab11$19,025
MyrbetriqMirabegron16$15,030
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,714
Breo ElliptaFluticasone/Vilanterol26$10,962
TradjentaLinagliptin13$10,771
GemtesaVibegron18$10,466
InvokametCanagliflozin/Metformin Hcl11$6,249
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$5,861
Albuterol Sulfate HfaAlbuterol Sulfate141$5,211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$14$89,55887 claims
Novo NordiskOzempic, Rybelsus$22$64,49856 claims
Lilly USA, LLCTrulicity$72$41,49318 claims
PfizerEliquis$37$24,02719 claims
Astellas Pharma US IncMyrbetriq$17$15,03016 claims
Sumitomo Pharma America, Inc.Gemtesa$16$10,46618 claims
AbbVieSynthroid$127$4,31747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in Rensselaer

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →